In a just published Form 13, filed with the US Securities and Exchange Commission (SEC), Alimera Sciences Inc. (NASDAQ:ALIM) reported that Intersouth Partners Vi Lp has picked up 300,168 of common stock as of 2017-06-08.
The acquisition brings the aggregate amount owned by Intersouth Partners Vi Lp to a total of 300,168 representing less than 0.5% stake in the company.
For those not familiar with the company, Alimera Sciences, Inc. (Alimera) is a pharmaceutical company. The Company is engaged in the research, development and commercialization of prescription ophthalmic pharmaceuticals. The Company operates through two segments: U.S. and International. The Company focuses on diseases affecting the back of the eye or retina. The Company’s product is ILUVIEN, which is developed to treat diabetic macular edema (DME). DME is a disease of the retina that affects individuals with diabetes and can lead to severe vision loss and blindness. In the United States, ILUVIEN is indicated for the treatment of DME in patients who have been treated with a course of corticosteroids and did not have a rise in intraocular pressure (IOP). In the European Economic Area (EEA) countries, ILUVIEN is indicated for the treatment of vision impairment associated with DME considered insufficiently responsive to available therapies.
A glance at Alimera Sciences Inc. (NASDAQ:ALIM) key stats reveals a current market capitalization of 88.28 Million based on 64.90 Million shares outstanding and a price at last close of $1.38 per share.
Looking at insider activity, there are a few transactions worth noting.
Specifically, on 2015-12-08, Flynn picked up 27,530 at a purchase price of $3.04. This brings their total holding to 728,718 as of the date of the filing.
On the sell side, the most recent transaction saw Myers unload 21,172 shares at a sale price of $1.39. This brings their total holding to 180,861.
It’s possible to gauge a company’s potential by tracking the activity of its major holders, as well as checking in on insider activity such as those transactions listed above. We’ll be keeping an eye on Alimera Sciences Inc. (NASDAQ:ALIM) as things move forward to see if its progress aligns with these transactions.
Subscribe below and we’ll keep you on top of what’s happening before it moves markets.